Key Medicine Shortages December 2023 here
Includes:
Co-trimoxazole 40mg/200mg/5ml oral suspension sugar free, Dicycloverine 10mg/5ml oral solution, Fluticasone 400microgram/unit dose nasal drops and Rifampicin 150mg capsules
Posted: Thursday, December 7, 2023
Category - Medicines Update
Key Medicine Shortages December 2023 here
Includes:
Co-trimoxazole 40mg/200mg/5ml oral suspension sugar free, Dicycloverine 10mg/5ml oral solution, Fluticasone 400microgram/unit dose nasal drops and Rifampicin 150mg capsules
Posted: Friday, December 1, 2023
Category - Medicines Update
General key messages
Posted: Thursday, November 30, 2023
Category - Medicines Update
Key Points
Posted: Wednesday, November 29, 2023
Category - Medicines Update
Thiamine supplementation is required in patients at risk of re-feeding syndrome regardless of route of nutrition (IV, oral, enteral feeding tube) and should be started immediately before nutrition is re-introduced where possible
Posted: Monday, November 27, 2023
Category - Medicines Update
Key messages:
Posted: Wednesday, November 22, 2023
Category - Formulary Update
Posted: Friday, November 17, 2023
Category - Medicines Update
Key Messages:
Posted: Monday, November 13, 2023
Category - Medicines Update
Key Medicine Shortages October 2023 here
Includes:
Bisacodyl (Dulcolax®) 5mg suppositories, Bumetanide 1mg and 5mg tablets, Lamotrigine 5mg dispersible tablets, Pancreatin (Pancrease® HL) gastro-resistant tablets and Testosterone enantate 250mg/ml solution for injection ampoules.
Posted: Wednesday, November 8, 2023
Category - Medicines Update
These clinical guidelines have been comprehensively updated and coincide with publication of revised European heart failure (HF) guidelines by European Society of Cardiology, August 2023
Posted: Tuesday, November 7, 2023
Category - Medicines Update
Key messages:
Following discussion at the West of Scotland Cardiology Prescribing Group, the decision has been made to change to prescribing of prasugrel in the majority of future patients undergoing percutaneous coronary intervention (PCI)
Prasugrel will replace ticagrelor, in combination with aspirin, as the dual antiplatelet therapy (DAPT) agent of choice post-PCI for the majority of patients from Monday 06th November 2023